Phase I Clinical Trial of Endovenous Administration of Conditionally Replicative Adenovirus ICOVIR-5 in Patients With Locally Advanced or Metastatic Melanoma
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose
The highest dose where less than two out of three or six patients suffered dose limiting toxicity.
Ramon Salazar, MD PhD
Institut Catala D'Oncologia
Spain: Agencia Española de Medicamentos y Productos Sanitarios